Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study.
about
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseCarboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTORUrinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric studyThe HALT polycystic kidney disease trials: design and implementation.Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.Hypertension in autosomal dominant polycystic kidney disease.A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney diseaseKidney-specific inactivation of Ofd1 leads to renal cystic disease associated with upregulation of the mTOR pathwayLow-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trialRapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease.Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.Soluble klotho and autosomal dominant polycystic kidney disease.Evaluation of urine biomarkers of kidney injury in polycystic kidney disease.PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?Huge bilateral polycystic kidneys with suspicion of malignancy, recurrent bleeding in cysts, and acute abdomen.The fetal environment: a critical phase that determines future renal outcomes in autosomal dominant polycystic kidney diseaseDefective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy.Toward proof of concept of a one health approach to disease prediction and controlProspects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases.The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathwayRapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.
P2860
Q24186484-13A80B65-0C17-48ED-8DA3-91527BECB7F0Q24300205-EC836EE5-B507-4BFD-BB92-713B62E9ABB7Q28484968-E112C5CA-32CB-4B24-BD21-32965659C239Q33571347-F7742CA4-59A0-43D5-8356-67823ACF5FC0Q33702386-C46E74CD-A3DA-4797-91BB-4521D9031EB0Q33754691-DF57D897-5A73-4561-8AD7-B18947F40313Q33784024-EE86C72F-5495-498D-80E3-1A1BC1AF5FB4Q33947853-B147FE61-E635-4BD5-9016-C4DA86880097Q34446891-C7E7426E-5568-4839-B262-93639CE7E022Q34475383-CCEDB239-3238-4658-AE72-3AB7D6DE152DQ34627120-255B93B6-3D70-4D69-AD13-2E94DA5BA540Q35758541-F0029C55-B6A8-4E4D-A2CB-AF26D518D7FBQ35870104-B5080F31-D68F-4C48-98F9-8D2B760CD8E4Q36025665-5D0AC119-0544-4F8A-AF1B-28F13517F8E3Q36198533-692C9577-5812-47B8-8165-CCA4344846A8Q36371342-3C0DA916-B9B1-4C04-9DBC-D89373AF11C7Q37092766-F7DDEC4E-BFA7-4AB2-9EAA-49A9B532FBC0Q37343743-5A65A8F5-F6E8-4F2B-87B0-05301A003713Q37760379-38348FCC-0827-4378-95C6-D8E164149742Q38232593-7FF7FF69-C7AC-4F6D-9EF8-BD03E27C1C6CQ39930668-DD606C81-4CD6-41B2-9FF5-531F55F9BD22Q41247634-51BC535B-75FD-4C17-B15A-3A494E534DB4Q43272350-474E5541-29D6-4052-991C-7D94D3A907C8Q51554260-3678BBA0-6BBB-4A84-8F86-271F2C4FDB0B
P2860
Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Clinical proof-of-concept tria ...... y disease: SUISSE ADPKD study.
@ast
Clinical proof-of-concept tria ...... y disease: SUISSE ADPKD study.
@en
Clinical proof-of-concept tria ...... y disease: SUISSE ADPKD study.
@nl
type
label
Clinical proof-of-concept tria ...... y disease: SUISSE ADPKD study.
@ast
Clinical proof-of-concept tria ...... y disease: SUISSE ADPKD study.
@en
Clinical proof-of-concept tria ...... y disease: SUISSE ADPKD study.
@nl
prefLabel
Clinical proof-of-concept tria ...... y disease: SUISSE ADPKD study.
@ast
Clinical proof-of-concept tria ...... y disease: SUISSE ADPKD study.
@en
Clinical proof-of-concept tria ...... y disease: SUISSE ADPKD study.
@nl
P2093
P2860
P356
P1433
P1476
Clinical proof-of-concept tria ...... y disease: SUISSE ADPKD study.
@en
P2093
Andreas D Kistler
Andreas L Serra
Diane Poster
Dominik Weishaupt
Frank Tschirch
Marian Struker
Rudolf P Wüthrich
P2860
P2888
P356
10.1186/1471-2369-8-13
P577
2007-09-15T00:00:00Z
P5875
P6179
1015632741